GO:0034899 trimethylamine monooxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034899 trimethylamine monooxygenase activity catalyzes the NADPH- and O2-dependent conversion of trimethylamine (TMA) to trimethylamine N-oxide (TMAO).
• The reaction is a flavin-containing monooxygenase (FMO) type oxidation, classically associated with FMO3 in humans.
• TMAO generated by this activity is a circulating metabolite linked to cardiometabolic disease, inflammation, and thrombosis.
• Loss of FMO3 function causes primary trimethylaminuria, a disorder of TMA accumulation with a characteristic fish-like odor.
• TMAO produced by this activity can activate PERK and ER stress pathways, contributing to metabolic dysfunction.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are key tools for dissecting GO:0034899 in disease.
Description
GO:0034899 trimethylamine monooxygenase activity is a molecular function defined by the catalytic conversion of N,N,N-trimethylamine (TMA) to N,N,N-trimethylamine N-oxide (TMAO) using NADPH, H+, and O2 as co-substrates and producing NADP+ and H2O. This activity is central to the metabolism of dietary choline, carnitine, and betaine by the gut microbiota and the subsequent host oxidation of TMA. Because TMAO is a circulating metabolite with broad systemic effects, understanding this enzymatic step is important for researchers in metabolism, cardiovascular biology, and immunology. The reaction is typically associated with flavin-containing monooxygenases, especially FMO3 in humans, and its dysregulation has been linked to both rare metabolic disorders and common cardiometabolic diseases. In this article, we summarize the mechanism, key genes, disease relevance, and experimental approaches for studying GO:0034899, with a focus on CRISPR-based models and functional genomics.
trimethylamine monooxygenase activity At A Glance
| GO ID | GO:0034899 |
|---|---|
| GO term | trimethylamine monooxygenase activity |
| Ontology | molecular_function |
| Synonym | (none) |
| Definition | Catalysis of the reaction: N,N,N-trimethylamine + NADPH + H+ + O2 = N,N,N-trimethylamine N-oxide + NADP+ + H2O. |
| Major function | Oxidation of trimethylamine to trimethylamine N-oxide |
| Cofactors/substrates | NADPH, H+, O2, N,N,N-trimethylamine |
| Products | N,N,N-trimethylamine N-oxide, NADP+, H2O |
| Typical enzyme class | Flavin-containing monooxygenase (e.g., FMO3 in humans) |
| Disease relevance | Primary trimethylaminuria; cardiometabolic and inflammatory conditions linked to TMAO |
What Is GO:0034899?
In our own words, GO:0034899 trimethylamine monooxygenase activity describes the enzymatic catalysis of the reaction: N,N,N-trimethylamine + NADPH + H+ + O2 = N,N,N-trimethylamine N-oxide + NADP+ + H2O. This is an oxidation reaction in which the nitrogen of trimethylamine is converted to an N-oxide, consuming reducing equivalents from NADPH and molecular oxygen. The activity is a monooxygenase-type function and is often attributed to flavin-containing monooxygenase enzymes, particularly FMO3 in humans. The term is a molecular_function in the Gene Ontology and does not by itself specify a particular gene product, but in practice it is used to annotate enzymes that carry out this TMA-to-TMAO conversion.
Why Is trimethylamine monooxygenase activity Important in Cell Biology?
GO:0034899 trimethylamine monooxygenase activity is important because it produces TMAO, a metabolite that has been repeatedly associated with cardiovascular risk, metabolic dysfunction, and inflammation. The reaction represents a key host-microbe interface: gut bacteria generate TMA from dietary precursors, and host monooxygenases convert it to TMAO, which then acts on multiple tissues. Defects in this activity cause primary trimethylaminuria, a rare but well-characterized metabolic disorder. In addition, TMAO generated through this activity has been shown to activate PERK and ER stress pathways, promote trained immunity, and impair adipose tissue function, making it a compelling target for mechanistic and translational studies.
• Produces TMAO, a circulating metabolite linked to cardiometabolic disease risk.
• Represents a critical host-microbe metabolic axis involving dietary choline, carnitine, and betaine.
• Loss of function causes primary trimethylaminuria, characterized by TMA accumulation and fish-like odor.
• TMAO from this activity can activate PERK and ER stress, contributing to metabolic dysfunction.
• TMAO promotes trained immunity and inflammatory responses via ER stress, mitochondrial ROS, and glycolysis.
• Adipocyte FMO3-derived TMAO can induce white adipose tissue dysfunction and inflammasome activation during ageing.
• TMAO has been implicated in ischemic stroke and other vascular pathologies.
• The activity is a potential therapeutic target for modulating TMAO levels in cardiometabolic disease.
• CRISPR models enable causal testing of FMO3 and related genes in TMAO biology.
• Studying this activity informs probiotic and microbiome-based interventions.
Molecular Mechanism of trimethylamine monooxygenase activity
Substrate binding and cofactor requirements
In simple terms: The enzyme grabs TMA and uses NADPH and oxygen to modify it.
The reaction catalyzed by GO:0034899 requires N,N,N-trimethylamine as the substrate, along with NADPH, H+, and O2 as co-substrates. The enzyme binds TMA and positions it for oxidation, while NADPH provides reducing equivalents and molecular oxygen is activated for insertion into the substrate. This monooxygenase-type chemistry is characteristic of flavin-containing monooxygenases, which use FAD as a prosthetic group to activate oxygen.
Catalytic oxidation of TMA to TMAO
In simple terms: The enzyme turns TMA into TMAO by adding an oxygen atom.
During catalysis, the nitrogen of TMA is oxidized to form N,N,N-trimethylamine N-oxide (TMAO), with concomitant production of NADP+ and H2O. This oxidation converts a volatile amine into a more polar N-oxide, which is the form that circulates systemically and exerts biological effects. The reaction is a classic example of a flavin-dependent monooxygenation, and in humans it is predominantly attributed to FMO3.
Enzyme identity and tissue distribution
In simple terms: In humans, FMO3 is the main enzyme doing this job, especially in the liver.
The activity defined by GO:0034899 is most commonly associated with flavin-containing monooxygenase 3 (FMO3) in humans, which is highly expressed in the liver. FMO3 catalyzes the conversion of TMA to TMAO, and its expression levels influence circulating TMAO concentrations. Other FMO family members may contribute to this activity in different tissues or species, but FMO3 is the best-characterized enzyme for this function.
Regulation of enzyme activity
In simple terms: The amount and activity of the enzyme can change with diet, hormones, and disease.
FMO3 expression and activity can be regulated by dietary factors, hormones, and inflammatory signals, although the precise mechanisms vary by context. Because TMAO levels depend on both microbial TMA production and host FMO3 activity, changes in either arm can alter the flux through GO:0034899. In ageing and metabolic disorders, adipocyte FMO3-derived TMAO has been shown to promote inflammasome activation, suggesting that regulation of this activity is relevant to disease progression.
Downstream signaling by TMAO
In simple terms: The TMAO made by this enzyme can trigger stress and inflammation in cells.
TMAO generated by GO:0034899 can bind and activate PERK, leading to ER stress and metabolic dysfunction. It also enhances trained immunity through ER stress, mitochondrial ROS, and glycolysis pathways, thereby increasing inflammation. These downstream effects link the enzymatic activity to systemic immunometabolic responses and cardiovascular risk.
Key Genes Involved in GO:0034899 trimethylamine monooxygenase activity
The following genes and proteins are directly or indirectly involved in trimethylamine monooxygenase activity (GO:0034899) and its biological consequences.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FMO3 | Primary human enzyme catalyzing TMA to TMAO | Central to GO:0034899; mutations cause trimethylaminuria |
| FMO1 | Flavin-containing monooxygenase family member | Potential contributor to TMA oxidation in some tissues |
| FMO2 | Flavin-containing monooxygenase family member | Related monooxygenase with overlapping substrate specificity |
| FMO4 | Flavin-containing monooxygenase family member | Less characterized; possible minor role in amine oxidation |
| FMO5 | Flavin-containing monooxygenase family member | Distinct substrate preferences; not a major TMA oxidase |
| PERK (EIF2AK3) | ER stress sensor activated by TMAO | Mediates TMAO-induced metabolic dysfunction |
| NLRP3 | Inflammasome component activated by TMAO | Links TMAO to adipose tissue inflammation |
| TNF | Pro-inflammatory cytokine induced by TMAO | Marker of TMAO-driven inflammation |
| IL6 | Pro-inflammatory cytokine induced by TMAO | Marker of TMAO-driven inflammation |
| IL1B | Inflammasome-dependent cytokine | Readout of NLRP3 activation by TMAO |
| CHDH | Choline dehydrogenase (microbial) | Microbial TMA generation from choline |
| CutC | Choline TMA-lyase (microbial) | Microbial TMA production; upstream of GO:0034899 |
| CutD | CutC activating enzyme (microbial) | Required for microbial TMA lyase activity |
| CntA | Carnitine TMA-lyase (microbial) | Microbial TMA production from carnitine |
| YeaW | Carnitine monooxygenase (microbial) | Microbial TMA generation from carnitine |
| YeaX | Carnitine monooxygenase subunit (microbial) | Microbial TMA generation from carnitine |
| FMO3 variants | Polymorphisms affecting enzyme activity | Associated with trimethylaminuria and TMAO levels |
How Is trimethylamine monooxygenase activity Regulated?
The activity of trimethylamine monooxygenase (GO:0034899) is regulated at multiple levels. In humans, FMO3 expression is influenced by dietary factors, hormones, and inflammatory status, and genetic variants in FMO3 can alter enzyme activity and TMAO production. Because TMAO is derived from microbial TMA, the overall flux through this activity also depends on the composition and metabolic output of the gut microbiota, which can be modulated by diet and probiotics. In ageing and metabolic disease, adipocyte FMO3-derived TMAO promotes inflammasome activation, indicating that local regulation of this activity in adipose tissue contributes to systemic metabolic dysfunction. Additionally, TMAO itself can activate PERK and ER stress pathways, creating feedback that may further influence cellular metabolism and inflammation.
trimethylamine monooxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FMO3 | Primary trimethylaminuria | FMO3 knockout or point-mutation cell lines; TMA/TMAO measurement |
| FMO3 | Cardiometabolic disease / atherosclerosis | FMO3 overexpression and knockout in hepatocytes or macrophages |
| FMO3 | Adipose tissue dysfunction and ageing | Adipocyte-specific FMO3 knockout or knock-in mouse models |
| PERK (EIF2AK3) | TMAO-induced ER stress and metabolic dysfunction | PERK knockout cells treated with TMAO |
| NLRP3 | TMAO-driven inflammasome activation | NLRP3 knockout macrophages or adipocytes |
Primary trimethylaminuria
Primary trimethylaminuria is an inherited disorder caused by loss-of-function mutations in FMO3, leading to defective trimethylamine monooxygenase activity (GO:0034899). Affected individuals accumulate trimethylamine, which is excreted in sweat, breath, and urine, producing a characteristic fish-like odor. This condition directly illustrates the physiological importance of the TMA-to-TMAO conversion and is a classic monogenic disorder of this enzymatic activity.
Cardiometabolic disease and atherosclerosis
Elevated circulating TMAO, the product of GO:0034899, has been associated with increased risk of cardiometabolic diseases, including atherosclerosis and cardiovascular events. TMAO can activate PERK and promote metabolic dysfunction, and it enhances trained immunity via ER stress, mitochondrial ROS, and glycolysis, thereby amplifying inflammation in cardiovascular tissues. These mechanisms link the enzymatic activity to systemic immunometabolism and plaque instability.
Metabolic disorders and adipose tissue dysfunction
Adipocyte FMO3-derived TMAO induces white adipose tissue dysfunction and metabolic disorders by promoting inflammasome activation during ageing. This suggests that local TMAO production via GO:0034899 in adipose tissue contributes to age-related metabolic decline. The finding also highlights FMO3 as a potential target for interventions aimed at reducing TMAO-driven metabolic inflammation.
Ischemic stroke and vascular inflammation
Gut microbe-generated TMAO has been implicated in ischemic stroke, where it may exacerbate vascular inflammation and thrombotic risk. Because TMAO is produced by GO:0034899 from microbial TMA, modulation of this activity could influence stroke outcomes. Further studies are needed to define the precise causal pathways, but the association underscores the clinical relevance of this enzymatic function.
From trimethylamine monooxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FMO3 loss reduce TMAO production? | FMO3 knockout cell lines (e.g., HepG2, primary hepatocytes) |
| Which FMO3 variants impair catalytic activity? | Point-mutation knock-in of specific FMO3 alleles |
| Can tagged FMO3 be used to track localization? | Knock-in of fluorescent or epitope tags at the endogenous FMO3 locus |
| Does FMO3 overexpression increase TMAO and inflammation? | FMO3 overexpression in adipocytes or hepatocytes |
| Is PERK required for TMAO-induced metabolic dysfunction? | PERK knockout cells treated with TMAO |
| Does NLRP3 mediate TMAO-induced adipose inflammation? | NLRP3 knockout macrophages or adipocytes |
How to Study the trimethylamine monooxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | TMA, TMAO, and related metabolites | Quantifying flux through GO:0034899 in cells and tissues |
| Enzymatic activity assay | Conversion of TMA to TMAO in vitro | Validating FMO3 or candidate enzyme activity |
| CRISPR knockout | Loss-of-function effects on TMAO production | Testing causal role of FMO3 or PERK |
| CRISPR point mutation | Effect of specific FMO3 variants | Modeling trimethylaminuria-associated alleles |
| RNA-seq | Transcriptional changes induced by TMAO | Identifying downstream pathways |
| Proteomics | Protein expression and modifications | Mapping TMAO-responsive signaling |
| Immunofluorescence | Localization of FMO3 or tagged proteins | Studying enzyme distribution in tissues |
| Inflammasome assays | NLRP3 activation and IL-1beta release | Linking TMAO to adipose inflammation |
Enzymatic activity assays
Direct measurement of trimethylamine monooxygenase activity (GO:0034899) can be performed using cell or tissue lysates incubated with TMA, NADPH, and O2, followed by quantification of TMAO production by mass spectrometry or colorimetric assays. These assays are essential for confirming that a candidate enzyme, such as FMO3, carries out the reaction.
Metabolite profiling by mass spectrometry
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is widely used to quantify TMA, TMAO, choline, carnitine, and betaine in biological samples. This approach enables researchers to assess flux through GO:0034899 in cells, animal models, and human cohorts.
CRISPR-based functional genomics
CRISPR knockout, point-mutation, and knock-in models allow causal testing of genes involved in TMAO biology, including FMO3 and its regulators. Pooled CRISPR screens can identify modifiers of TMAO-induced phenotypes, such as ER stress or inflammasome activation.
Transcriptomic and proteomic profiling
RNA-seq and proteomics can reveal how FMO3 expression and TMAO production affect cellular pathways, including ER stress, inflammation, and metabolism. These methods help connect GO:0034899 activity to downstream gene expression programs in disease models.
How CRISPR Can Be Used to Study GO:0034899 trimethylamine monooxygenase activity
Knockout
CRISPR knockout of FMO3 or related genes can abolish trimethylamine monooxygenase activity (GO:0034899), leading to reduced TMAO production and altered downstream phenotypes. Knockout models are useful for establishing causality between the enzymatic activity and disease-associated outcomes such as inflammation or metabolic dysfunction.
Point Mutation
Point mutations in FMO3 that are associated with primary trimethylaminuria can be introduced using CRISPR to model the loss of enzymatic activity. Such models help determine how specific amino acid changes affect TMA oxidation and TMAO levels.
Knock-in
Knock-in of tags or reporter sequences at the endogenous FMO3 locus allows tracking of enzyme expression, localization, and dynamics in live cells. This approach can also be used to introduce disease-relevant variants or regulatory elements.
Overexpression
Overexpression of FMO3 or other candidate enzymes can increase TMAO production and amplify downstream effects, such as ER stress and inflammasome activation. Overexpression models are valuable for studying gain-of-function mechanisms and for screening potential inhibitors of GO:0034899.
How EDITGENE Supports trimethylamine monooxygenase activity Research
Researchers studying trimethylamine monooxygenase activity-related genes often need to determine whether a candidate gene is causally involved in TMAO production, ER stress, or inflammation. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for trimethylamine monooxygenase activity research.
Frequently Asked Questions About trimethylamine monooxygenase activity
What is trimethylamine monooxygenase activity?
Trimethylamine monooxygenase activity (GO:0034899) is the enzymatic catalysis of the reaction converting N,N,N-trimethylamine to N,N,N-trimethylamine N-oxide using NADPH, H+, and O2.
What genes are involved in trimethylamine monooxygenase activity?
The primary human gene is FMO3, which encodes a flavin-containing monooxygenase that oxidizes TMA to TMAO; other FMO family members may also contribute.
What is the reaction catalyzed by GO:0034899?
The reaction is: N,N,N-trimethylamine + NADPH + H+ + O2 = N,N,N-trimethylamine N-oxide + NADP+ + H2O.
How is trimethylamine monooxygenase activity related to disease?
Loss of FMO3 activity causes primary trimethylaminuria, and elevated TMAO from this activity is associated with cardiometabolic disease, inflammation, and stroke.
What is the role of FMO3 in TMAO production?
FMO3 catalyzes the conversion of TMA to TMAO in the liver, and its expression levels directly influence circulating TMAO concentrations.
Can CRISPR be used to study trimethylamine monooxygenase activity?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models can be used to test the causal role of FMO3 and related genes in TMAO biology.
What diseases are linked to TMAO?
TMAO has been linked to atherosclerosis, cardiometabolic disease, adipose tissue dysfunction, and ischemic stroke.
How is trimethylamine monooxygenase activity measured?
It can be measured by enzymatic assays using TMA, NADPH, and O2, followed by quantification of TMAO by mass spectrometry or colorimetric methods.
What is primary trimethylaminuria?
Primary trimethylaminuria is a metabolic disorder caused by FMO3 mutations, leading to TMA accumulation and a fish-like odor.
What model systems are used to study GO:0034899?
Common models include hepatocyte and adipocyte cell lines, knockout or transgenic mice, and CRISPR-engineered cells for functional studies.
Conclusion
GO:0034899 trimethylamine monooxygenase activity is a key enzymatic function that converts microbial TMA into TMAO, a metabolite with broad implications for cardiometabolic disease, inflammation, and rare metabolic disorders such as primary trimethylaminuria. Understanding its mechanism, regulation, and disease connections requires integrating enzymology, metabolomics, and functional genomics. CRISPR-based models provide powerful tools to dissect the causal roles of FMO3 and related genes, and EDITGENE offers comprehensive services to support such research.
References
- 1. Guan B et al.. 2022. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases.. Acta Pharm Sin B 12(5):2129-2149 PMID: 35646540
- 2. Nabavi-Rad A et al.. 2022. The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management.. Gut Microbes 14(1):2108655 PMID: 35951774
- 3. Chen S et al.. 2019. Trimethylamine N-Oxide Binds and Activates PERK to Promote Metabolic Dysfunction.. Cell Metab 30(6):1141-1151.e5 PMID: 31543404
- 4. Adam MP et al.. 1993. Primary Trimethylaminuria.. PMID: 20301282
- 5. Saaoud F et al.. 2023. Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.. JCI Insight 8(1) PMID: 36394956
- 7. Ganapathy T et al.. 2025. Adipocyte FMO3-derived TMAO induces WAT dysfunction and metabolic disorders by promoting inflammasome activation in ageing.. Nat Commun 16(1):8873 PMID: 41053195
- 8. Li Z et al.. 2024. Gut Microbe-Generated Metabolite Trimethylamine-N-Oxide and Ischemic Stroke.. Biomolecules 14(11) PMID: 39595639
